SecBot SecBot
COURT-RULING ·Filed Jul 27, 2026

AZN

ASTRAZENECA PLC
NEUTRAL
Impact 3/10
Horizonmonths Processed3mo ago CourtCourt Ruling · govinfo.gov
Court ruling (district)
Actionable Insight • Neutral

This ruling is a procedural loss but carries negligible financial impact for AstraZeneca. The legal landscape for 340B contract pharmacy laws remains fragmented across circuits, with a potential Supreme Court petition or en banc Fourth Circuit decision as the next catalyst. Monitor for any circuit split resolution or legislative action, but no near-term trading signal from this ruling alone.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$172.48
T+0 close · Jul 28, 2026 · via day close
Latest settled
−2.34%
T+60 · $168.45
Vs SPY
−6.69%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 28 $172.48entry
  2. T+1 · 4mo ago +0.48%α +2.01% · $173.30
  3. T+5 · 4mo ago −9.78%α −13.89% · $155.62
  4. T+20 · 3mo ago −1.64%α −5.02% · $169.66
  5. T+60 · 27d ago −2.34%α −6.69% · $168.45
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

AstraZeneca's challenge to Maine's 340B contract pharmacy law (Chapter 103) was dismissed by the District of Maine. The court granted the state's motion to dismiss, finding AstraZeneca failed to state plausible claims for federal preemption, Contracts Clause violation, or Takings Clause violation. This is a loss for AstraZeneca in its effort to block state restrictions on manufacturer limits to 340B contract pharmacies, but the ruling is consistent with multiple other district and circuit court decisions on similar state laws, and the financial impact alleged by AstraZeneca ($3.6M/year in savings from a single-pharmacy limit) is trivial relative to its $265.7B market cap, making this a low-impact, confirmatory legal development with no immediate operational disruption.

Court Ruling Details

Ruling Date
Jul 27, 2026
Court
United States District Court for the District of Maine
Court Level
District
Judge
John C. Nivison
Case Type
regulatory
Ruling Type
motion to dismiss
Outcome
LOSS: ruling against this company
Appeal Timeline
1-2 years for First Circuit appeal
Precedent Risk
LOW

Key Facts

  • The District of Maine granted the state's motion to dismiss AstraZeneca's challenge to Maine's 340B contract pharmacy law (Chapter 103).
  • AstraZeneca alleged it would save $300,000 per month ($3.6 million per year) if it could limit covered entities to a single pharmacy.
  • The court found AstraZeneca's nonconclusory allegations failed to state plausible claims for obstacle preemption, Contracts Clause, or Takings Clause violations.
  • This ruling is consistent with multiple other district and circuit court decisions upholding similar state 340B contract pharmacy laws.
  • AstraZeneca voluntarily participates in the 340B program and can choose to withdraw; the court noted no allegation that it intends to do so.

Financial Impact

AstraZeneca alleged $3.6M/year in potential savings from a single-pharmacy limit, which is immaterial relative to its $265.7B market cap. No damages were awarded or sought in this ruling.

revenueoperating costs

Risk Factors

  • Potential for adverse circuit split if other circuits rule differently on similar state laws, creating uncertainty.
  • If the Fourth Circuit en banc reverses and upholds a preliminary injunction against a similar state law, it could create a circuit split and increase Supreme Court certiorari risk.
  • Continued state-level legislative activity on 340B contract pharmacy could incrementally increase compliance costs across multiple states.

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (35 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 court opinion.

DocumentAccession Number
COURT-RULING Data (Synthetic)court-0b6e0466c2-AZN

Track record

77 reports on AZN

Performance horizon

19 of 38 bullish or bearish reports moved the stock their way by T+5. Best: +20.72% at T+60 after the Aug 17, 2026 report. 29 of 38 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Bullish 6/10 Entry price pending
  2. Nov 16, 2026today 6-K Bullish 6/10 Entry $185.55 Now $184.02 −0.82% settles Nov 23
  3. Nov 16, 2026today 6-K Bullish 6/10 Entry $185.31 Now $184.02 −0.70% settles Nov 23
  4. Nov 16, 2026today 6-K Bullish 5/10 Entry $185.09 Now $184.02 −0.58% settles Nov 23
  5. Nov 4, 202612d ago Institutional Cluster Mixed 3/10 Entry $186.85 to $184.38 Now $184.02 −1.51% ▼ −1.32% −4.61% vs SPY
  6. Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
  7. Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
  8. Oct 30, 202617d ago 6-K Neutral 5/10 Entry $186.65 to $186.43 Now $184.02 −1.41% ▼ −0.12% +2.59% vs SPY
  9. Oct 27, 202620d ago 6-K Bullish 5/10 Entry $170.08 to $183.88 Now $184.02 +8.20% ▲ +8.11% +10.10% vs SPY
  10. Oct 22, 202625d ago 6-K Bullish 6/10 Entry $172.57 to $173.46 Now $184.02 +6.63% ▲ +0.51% −0.19% vs SPY
Showing 10 of 77

US Market Status

Market Closed · Opens Wed (10h 25m)

Subscribe to SecBot

Get Real-Time Court Ruling Intelligence

Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
⚖ Court Ruling · govinfo.gov Report published Jul 31, 2026